Skip to main content
DongKoo Bio & Pharma Co., Ltd. logo

DongKoo Bio & Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 006620 ISIN · KR7006620009 KO Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2019-11-07 Transaction in Own Shar…
Country KR South Korea
Listing KO 006620

About DongKoo Bio & Pharma Co., Ltd.

https://www.dongkoo.com/eng/

DongKoo Bio & Pharma Co., Ltd. is a biopharmaceutical company that manufactures and sells a range of pharmaceuticals and health supplements. The company holds a leading position in the dermatology prescription market, with a product portfolio that includes antihistamines, analgesics, antipyretics, and digestants. Strategically expanding beyond traditional pharmaceuticals, DongKoo Bio & Pharma is focused on the biotechnology sector, particularly the development of stem cell-based therapies. This growth is pursued through an "Open Innovation" model to build a pipeline of differentiated products, supported by its research centers and PIC/s compliant GMP manufacturing facilities.

Recent filings

Filing Released Lang Actions
신탁계약에의한취득상황보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Acquisition of Treasury Shares via Trust Contract' (신탁계약등에의한취득상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the company's (DongKoo Bio & Pharma) share buyback activity through a trust agreement with Mirae Asset Daewoo. This type of filing specifically reports the company's transactions in its own shares (share repurchases). According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct category for reports regarding a company buying back its own shares.
2019-11-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (DART system) to report insider transactions, specifically share acquisitions by a director/major shareholder. This falls under the 'Director's Dealing' category.
2019-09-03 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders (Cho Yong-joon and special related parties) of Dongkoo Bio & Pharma. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant share ownership levels.
2019-09-03 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for DongKoo Bio&Pharma, covering the period from January 1, 2019, to June 30, 2019. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) is classified as an Interim / Quarterly Report (IR). H1 2019
2019-08-14 Korean
주요사항보고서(자기주식취득신탁계약체결결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities regarding the decision to enter into a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 체결 결정). This is a direct announcement of a company's decision to buy back its own shares through a trust, which falls under the category of 'Transaction in Own Shares'.
2019-08-06 Korean
분기보고서 (2019.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Dongkoo Bio & Pharma, covering the period from January 1, 2019, to March 31, 2019. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.